Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Absolute Bioavailability Clear all
Completed Phase 1 Interventional

OCR002-SP103 - Oral Immediate Release Study

NCT03846843
View directory record Official record
Conditions
Cirrhosis
Interventions
OCR-002 IR Oral Tablet, OCR-002 Oral Solution, OCR-002 IV Solution
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

NCT04924140
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Aducanumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

NCT00520169
View directory record Official record
Conditions
Healthy
Interventions
intranasal ketamine
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

NCT06180954
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LOXO-305, LOXO-305
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

NCT02782975
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
aducanumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers

NCT01875939
View directory record Official record
Conditions
Effect of Food
Interventions
Oral WCK2349, IV WCK771
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

NCT02676830
View directory record Official record
Conditions
Dyslipidemia
Interventions
K-312 100 mg, K-312 100 ug C14 IV
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
25 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

NCT04454918
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, [14C]-TAK-906 Oral Solution
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fentanyl Patch Pharmacokinetics in Healthy Adults

NCT02531971
View directory record Official record
Conditions
Peer Review, Research
Interventions
Intravenous fentanyl citrate, Duragesic®, Mylan generic fentanyl
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

NCT04833049
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

NCT00908271
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

NCT03811834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

NCT03960502
View directory record Official record
Conditions
Healthy Male Participants
Interventions
AG-881, [13C315N3]AG-881
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

NCT01967966
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0032
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

NCT04991766
View directory record Official record
Conditions
Healthy
Interventions
[¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glasdegib Absolute Bioavailability Study

NCT03270878
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Glasdegib Oral Tablet, Glasdegib IV infusion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

NCT05630287
View directory record Official record
Conditions
Healthy
Interventions
[14C]-Selpercatinib, Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

NCT00941109
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

NCT04234672
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects

NCT02390492
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Period 1 treatment, Period 2 treatment
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

NCT07508228
View directory record Official record
Conditions
Healthy
Interventions
Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability of Reslizumab in Healthy Subjects

NCT01990443
View directory record Official record
Conditions
Absolute Bioavailability
Interventions
Reslizumab IV, Reslizumab SC
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Microtracer [14C]ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 4, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

NCT06955741
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BMS-986446 IV, BMS-986446 SC, Acetaminophen, Loratadine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 4, 2026, 2:58 PM EDT